PTI / Peptide Therapy Index
Clinical and preclinical peptide therapy research — indexed by study type, assessed for evidence quality. Independent. No affiliates.
The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, and 7-5 for MOTS-c — overriding staff's negative briefing documents. The vote is non-binding; formal rulemaking must follow. Retatrutide was not evaluated under this framework: it is advancing toward a 2027 BLA filing on Phase 3 RCT data.
As of mid-2026, no completed randomized controlled trial has evaluated BPC-157 in any acute human muscle injury indication. The musculoskeletal efficacy record is entirely preclinical. One Phase 2 RCT — NCT07437547, targeting acute grade II hamstring strain — is recruiting, with co-primary endpoints of MRI-assessed injury volume at Day 14 and time to return to unrestricted sport.
Cone snail venom peptides — principally μ-, ω-, and α-conotoxin classes — reduce inflammation-induced pain in vivo through at least three mechanistically distinct pathways: voltage-gated sodium channel (NaV1.7/NaV1.8) blockade that silences peripheral nociceptor firing, N-type calcium channel (CaV2.2) inhibition that curtails spinal neurotransmitter release, and suppression of the NF-κB/COX-2 axis that drives prostaglandin-mediated peripheral sensitisation.
VRB-103 is a once-weekly oral amylin analog entering Phase 1 development by Verdiva Bio, with first-patient dosing confirmed in late July 2026. Whether it reproduces injectable-style weight-loss efficacy depends on three unresolved variables: oral bioavailability at therapeutically relevant concentrations, retention of AMY receptor selectivity after structural modification, and a tolerability profile that improves on pramlintide's nausea burden.
As of mid-2026, TB-500's wound-healing evidence base is mechanistically coherent and preclinically robust, but no completed human randomised controlled trial has evaluated the compound in any wound-healing indication. The July 2026 FDA PCAC review identified this absence as the definitive barrier to 503A compounding eligibility. The human trial gap is not narrowing — it remains structurally unbridged.
The TRIUMPH-1 topline readout — the primary obesity-without-diabetes arm of retatrutide's phase III programme — reports mean body-weight reductions of approximately 19% at 4 mg, 24% at 8 mg, and 28% at 12 mg over 80 weeks versus placebo. Cardiometabolic endpoints show dose-proportional improvements. The 80-week timepoint is the longest placebo-controlled pharmacological weight-loss dataset for any triple agonist in 2026.
The Peptide Therapy Index catalogues primary-source research on peptide therapies — clinical trials, preclinical studies, and evidence reviews — assessed for study type and quality. Every entry identifies whether the underlying evidence is from randomised controlled trials, animal models, case series, or review syntheses.
No commercial affiliations. No advertising. No supplements sold. Editorial standards →